• Corpus ID: 14044008

Radioimmunotherapy for breast cancer using indium-111/yttrium-90 BrE-3: results of a phase I clinical trial.

@article{Denardo1997RadioimmunotherapyFB,
  title={Radioimmunotherapy for breast cancer using indium-111/yttrium-90 BrE-3: results of a phase I clinical trial.},
  author={Sally J. Denardo and Elissa L. Kramer and Robert T. O’Donnell and Carol M. Richman and Qansy Salako and Sui Shen and M. Noz and Stephan D. Glenn and Roberto L. Ceriani and Gerald L. Denardo},
  journal={Journal of nuclear medicine : official publication, Society of Nuclear Medicine},
  year={1997},
  volume={38 8},
  pages={
          1180-5
        }
}
  • S. Denardo, E. Kramer, G. Denardo
  • Published 1 August 1997
  • Medicine, Biology
  • Journal of nuclear medicine : official publication, Society of Nuclear Medicine
UNLABELLED BrE-3 is a murine IgG1 monoclonal antibody that binds to 97% of human ductal breast cancer specimens. A previous study documented the ability of 111In-labeled 1,4-methyl-benzyl isothiocyanate diethylenetriamine pentaacetic acid (111In-MX-DTPA) BrE-3 to specifically target breast cancer tissue in patients, and the dosimetry derived from the pharmacokinetics suggested that a useful therapeutic index could be obtained with 90Y-MX-DTPA BrE-3. A Phase I maximum tolerated dose study was… 

Figures and Tables from this paper

A phase I trial of (90)Y-DOTA-anti-CEA chimeric T84.66 (cT84.66) radioimmunotherapy in patients with metastatic CEA-producing malignancies.
TLDR
This study demonstrates the feasibility of using (90)Y-DOTA-cT84.66 for antibody-guided radiation therapy and supports the predictions from preclinical and clinical data that RIT may be best applied in the minimal tumor burden setting.
Phase I Study of Yttrium-90 Radiolabeled M5A Anti-Carcinoembryonic Antigen Humanized Antibody in Patients with Advanced Carcinoembryonic Antigen Producing Malignancies.
TLDR
This study demonstrates the potential utility of the 90Y-DOTA-M5A anti-CEA mAb as a therapeutic antibody, and there is decreased immunogenicity compared with murine and chimeric mAbs, allowing for the potential of multiple administrations.
Safety, biodistribution, pharmacokinetics, and immunogenicity of 99mTc-labeled humanized monoclonal antibody BIWA 4 (bivatuzumab) in patients with squamous cell carcinoma of the head and neck
TLDR
The use of 99mTc-BIWA 4 for RIT studies in patients with HNSCC is supported, with absence of detectable HAHA responses, and the safety, tumor-targeting potential, pharmacokinetics, and immunogenicity of technetium-99m-labeled BIWA 4 are evaluated.
Pre-targeted radioimmunotherapy of human colon cancer xenografts in athymic mice using streptavidin-CC49 monoclonal antibody and 90Y-DOTA-biotin
TLDR
Pre-targeted radioimmunotherapy was safe at administered amounts of 90Y radioactivity, which were at least nine-fold higher than those previously determined to be lethal using directly labelled 90Y-monoclonal antibodies.
Radioimmunotherapy with 111 In / 90 Y2 IT-BAD-m 170 for Metastatic Prostate Cancer 1
TLDR
This study determined the toxicity and maximum tolerated dose (MTD) of In/ Y-2IT-BAD-m170 in patients with metastatic prostate cancer and the drugs were well tolerated, targeted metastases, and temporarily palliated pain.
A Phase I trial of 90Y-anti-carcinoembryonic antigen chimeric T84.66 radioimmunotherapy with 5-fluorouracil in patients with metastatic colorectal cancer.
TLDR
Results from this trial are encouraging and demonstrate the feasibility and possible advantages of combining continuous infusion 5-FU with 90Y-cT84.66 RIT in combination with continuous infusion 4-fluorouracil (5-FU), which reduces the development of human anti-chimeric antibody response, permitting multicycle therapy in a larger number of patients.
Radioimmunotherapy with 111in/90y-2it-BAD-m170 for metastatic prostate cancer
TLDR
The drugs were well tolerated, targeted metastases, and temporarily palliated pain, and the toxicity was almost exclusively confined to reversible myelosuppression in patients with metastatic prostate cancer.
A Phase I Trial of 90 YAnti-Carcinoembryonic Antigen Chimeric T 84 . 66 Radioimmunotherapy with 5-Fluorouracil in Patients with Metastatic Colorectal Cancer
TLDR
Results from this trial are encouraging and demonstrate the feasibility and possible advantages of combining continuous infusion 5-FU with Y-cT84.66 RIT, and RIT did not appear to increase nonhematopoietic toxicities associated with5-FU.
Imaging and phase I study of 111In- and 90Y-labeled anti-LewisY monoclonal antibody B3.
TLDR
When given to patients with carcinomas that express the LewisY antigen, 111In-mAb B3 demonstrated good tumor localization and the maximum tolerated dose (MTD) was determined to be 20 mCi, with myelosuppression as the DLT.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 36 REFERENCES
Radioimmunolocalization of metastatic breast carcinoma using indium-111-methyl benzyl DTPA BrE-3 monoclonal antibody: phase I study.
  • E. Kramer, S. Denardo, G. Denardo
  • Biology, Medicine
    Journal of nuclear medicine : official publication, Society of Nuclear Medicine
  • 1993
TLDR
It is estimated therapeutic radiation doses could be delivered to some tumors with tolerable toxicity byrapolating dosimetry from 111In-methyl benzyl isothiocyanate DTPA-BrE-3 to 90Y-MX-DTPA- BrE- 3.
Indium-111-labeled B72.3 monoclonal antibody in the detection and staging of breast cancer: a phase I study.
  • L. Lamki, A. Buzdar, J. Murray
  • Biology, Medicine
    Journal of nuclear medicine : official publication, Society of Nuclear Medicine
  • 1991
TLDR
The study suggests that this antibody has 100% sensitivity for primary breast cancers, but very poor detection rate of metastatic lesions in axillary lymph nodes; thus making it of questionable value in the initial staging process of this disease.
Radioimmunotherapy for breast cancer using escalating fractionated doses of 131I-labeled chimeric L6 antibody with peripheral blood progenitor cell transfusions.
TLDR
PBPC transfusion can modify the myelotoxicity of RAIT and can permit repetitive dosing; cyclosporin is a promising means to abrogate HAMA; and fractionation of intensive-dose RAIT may increase the antitumor effect and reduce normal organ toxicity.
Experimental therapy of human breast tumors with 131I-labeled monoclonal antibodies prepared against the human milk fat globule.
TLDR
The results show that the systemic injection of radioiodinated MoAbs against human milk fat globule destroy the epithelial cells of human breast tumors and control their growth for an appreciable length of time.
Body and blood clearance and marrow radiation dose of 131I-Lym-1 in patients with B-cell malignancies.
TLDR
Clearances and marrow radiation doses were remarkably constant among different patients and among different therapy doses for the same patient, and are potentially useful as an initial approximation for other mouse monoclonal antibodies of the same isotype.
Immunohistochemical Staining of Metastatic Ductal Carcinomas of the Breast by Monoclonal Antibodies used in Imaging and Therapy: A Comparative Study
TLDR
Most patients with metastatic ductal carcinoma have cancer tissue in which a high percent of cells will react to several of these selected MoAbs that target different epitopes, which makes these antibodies potential candidates to carry immunologically directed radioimmunotherapy and is an aid in selecting patients for treatment.
Engineering of antibodies for breast cancer therapy: construction of chimeric and humanized versions of the murine monoclonal antibody BrE-3.
TLDR
A new generation of human monoclonal antibodies should not, however, displace good murine antibodies that have resulted from years of arduous labor and minutious characterization since these murine antibody may have uniquely useful binding properties, and since they can be humanized.
Experimental immunotherapy of human breast carcinomas implanted in nude mice with a mixture of monoclonal antibodies against human milk fat globule components.
TLDR
The results attest to the effectiveness of unconjugated anti-human milk fat globule MoAbs to arrest human breast tumor growth in nu/nu mice and suggest that to best arrest tumor growth the use of a mixture of MoAbs should be considered.
Estimation of Radiation Absorbed Doses to the Red Marrow in Radioimmunotherapy
TLDR
A non-invasive method for estimating the radiation absorbed dose to the red marrow of patients who have received radiolabeled monoclonal antibodies (MoAb) has been developed and explored and has the potential for providing the therapist with a predictor of greater likelihood of myelotoxicity.
Salvage chemotherapy of breast cancer.
  • L. Norton
  • Medicine, Biology
    Seminars in oncology
  • 1994
TLDR
Future investigations should focus on the possibility of high complete response rates in ideal candidates using regimens that consist of very high chemotherapy doses with hematopoietic support or on new therapies that disrupt some step in the cellular processes of breast cancer.
...
1
2
3
4
...